BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Fluzoparib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Fluzoparib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05983237-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fluzoparib: Phase 1/2 readout est. (NCT05983237)
DESCRIPTION:Fluzoparib\, phase 1/2.\nStudy: Fluzoparib in Combination With 
 Camrelizumab and Temozolomide in Advanced Melanoma\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/fluzoparib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05983237
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691804-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT04691804)
DESCRIPTION:Fluzoparib\, phase 3\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: A Multicenter\, Randomized\, Double-Blind\, Placebo-Contr
 olled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and
  Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatme
 nt in Patients With Metastatic Castration-Resistant Prostate Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04691804
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06208410-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Fluzoparib: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:Fluzoparib\, phase 1/2.\nStudy: A Clinical Study of JS105 in Co
 mbination With Other Anti-tumor Therapies in Patients With Solid Tumors\nE
 stimated primary completion: 26 February 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827717-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT06827717)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Phase II Study of Irinotecan Lipo
 some (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metast
 atic Ewing Sarcoma\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06827717
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05576389-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT05576389)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Fluzoparib Combined With Camreliz
 umab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative 
 Breast Cancer: an Open\, Single Arm\, Multicenter Study\nEstimated primary
  completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/fluzoparib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05576389
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07033819-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07033819)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Neoadjuvant Treatment of Ovarian 
 Cancer With Fuzuloparib in Combination With Apatinib\nEstimated primary co
 mpletion: 20 June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/fluzoparib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07033819
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971211-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT06971211)
DESCRIPTION:Fluzoparib\, phase 2\, Metastatic Castration-Resistant Prostate
  Cancer.\nStudy: Radiotherapy Combined With Fluzopanib and Abiraterone Ace
 tate Tablets (II) Treatment for mCRPC\nEstimated primary completion: 30 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fluzopari
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 971211
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612814-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT06612814)
DESCRIPTION:Fluzoparib\, phase 3.\nStudy: PARP Inhibitor With CDK4/ 6 Inhib
 itor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer\nEstimated 
 primary completion: 30 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06612814
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321015-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07321015)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: A Single-Arm Phase Ⅱ Study of F
 luzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breas
 t Cance\nEstimated primary completion: 30 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07321015
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Fudan University Shanghai Cancer 
 Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05582499
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891093-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT05891093)
DESCRIPTION:Fluzoparib\, phase 3.\nStudy: Efficacy and Safety of Fluzoparib
  Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early
  Breast Cancer (BCTOP-L-A01)\nEstimated primary completion: 31 May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fluzoparib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05891093
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752550-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07752550)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Retlirafusp Alfa Combined With Ch
 emotherapy or Fuzuloparib for Triple-Negative Breast Cancer\nEstimated pri
 mary completion: 30 July 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/fluzoparib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07752550
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355010-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07355010)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: A Randomized\, Open-label\, Doubl
 e-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 fo
 r Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer\nEstimated 
 primary completion: 30 December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07355010
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894018-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT05894018)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Brachytherapy (Iodine-125 Seeds) 
 and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue S
 arcoma\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05894018
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954584-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT06954584)
DESCRIPTION:Fluzoparib\, phase 3.\nStudy: Fluzoparib+Bevacizumab/Dietary In
 tervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- A
 dvanced Ovarian Cancer\nEstimated primary completion: 1 May 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fluzoparib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06954584
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141771-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Fluzoparib: Phase 1/2 readout est. (NCT07141771)
DESCRIPTION:Fluzoparib\, phase 1/2.\nStudy: An Umbrella Study of Recurrent\
 , Extensive Stage Small Cell Lung Cancer Based on Molecular Typing\nEstima
 ted primary completion: 30 June 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07141771
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382713-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07382713)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Fluzoparib Plus Famitinib Mainten
 ance After First-Line Platinum Response in Advanced Ovarian Cancer\nEstima
 ted primary completion: 31 December 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07382713
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647653-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07647653)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Fluzoparib + Bevacizumab vs Olapa
 rib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian
  Cancer\nEstimated primary completion: 28 February 2031. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fluzoparib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07647653
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06255392-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Fluzoparib: Phase 3 readout est. (NCT06255392)
DESCRIPTION:Fluzoparib\, phase 3.\nStudy: Randomized\, Open\, Controlled\, 
 Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apa
 tinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-nega
 tive Advanced Breast Cancer\nEstimated primary completion: March 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fluzoparib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06255392
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353437-9052@assetmemo.bio
DTSTAMP:20261121T004053Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Fluzoparib: Phase 2 readout est. (NCT07353437)
DESCRIPTION:Fluzoparib\, phase 2.\nStudy: Fluzoparib as Adjuvant Treatment 
 in Patients With Germline Homologous Recombination Repair (HRR) Mutated Pr
 imary Breast Cancer (Flamenco)\nEstimated primary completion: 31 December 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fluzoparib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07353437
URL:https://assetmemo.bio/drug/fluzoparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
